1502873-99-5

Basic information

• Product Name: C₂₀H₁₉NO₅S
• Synonyms: C₂₀H₁₉NO₅S
• CAS NO: 1502873-99-5
• Molecular Weight: 385.441
• Mol File: 1502873-99-5.mol

Chemical Properties

• CAS DataBase Reference: C₂₀H₁₉NO₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₁₉NO₅S(1502873-99-5)
• EPA Substance Registry System: C₂₀H₁₉NO₅S(1502873-99-5)

Safety Data

• Hazardous Substances Data: 1502873-99-5(Hazardous Substances Data)

Upstream product

• 2756-87-8 methyl hydrogen fumarate 
• 17081-97-9 methyl (E)-4-chloro-4-oxo-2-butenoate 
• 112111-43-0 Modafinil 
• 776-74-9 Bromodiphenylmethane 
• 63547-22-8 (benzhydrylthio)acetic acid 
• 68524-30-1 2-(diphenylmethylthio)acetamide 
• 68524-29-8 benzhydrylsulfanyl acetyl chloride 

Downstream Products

• 1502874-00-1 C₁₉H₁₇NO₅S 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss.

COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES

Disclosed are compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. Provided are also pharmaceutical compositions comprising an effective amount of the above compounds for treating neurological degenerative disorders and neurological diseases, which may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used for the treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, psychiatric/neurodegenerative disorders, ADHD, psychiatric/neurodegenerative disorders, depersonalization disorder, cognitive enhancement, fatigue, post-chemotherapy cognitive impairment and weight loss.